Show source-provided references
1. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
10.1038/s41591-021-01544-x ↗2. IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
10.1158/2326-6066.CIR-21-0457 ↗4. Cascade Immune Activation of Self-Delivery Biomedicine for Photodynamic Immunotherapy Against Metastatic Tumor
10.1002/smll.202205694 ↗5. The kynurenine pathway implicated in patient delirium: Possible indications for indoleamine 2,3 dioxygenase inhibitors
10.1172/JCI164577 ↗7. Huang, D., Wu, T., Lan, S., Liu, C., Guo, Z., and Zhang, W. (2022). In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors. Biomaterials, 289.
10.1016/j.biomaterials.2022.121808 ↗10. Zhao, H., Wang, Z., Yang, S., Zhang, R., Guo, J., and Yang, D. (2024). Energy-storing DNA-based hydrogel remodels tumor microenvironments for laser-free photodynamic immunotherapy. Biomaterials, 309.
10.1016/j.biomaterials.2024.122620 ↗11. Supramolecular artificial Nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy
10.1126/sciadv.adn8079 ↗12. Novel PdPtCu Nanozymes for Reprogramming Tumor Microenvironment to Boost Immunotherapy Through Endoplasmic Reticulum Stress and Blocking IDO-Mediated Immune Escape
10.1002/smll.202303596 ↗13. Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy
10.1016/j.apsb.2024.05.010 ↗14. Fox, E., Oliver, T., Rowe, M., Thomas, S., Zakharia, Y., Gilman, P.B., Muller, A.J., and Prendergast, G.C. (2018). Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Front. Oncol., 8.
10.3389/fonc.2018.00370 ↗15. Nanomedicine and cancer immunotherapy: Focus on indoleamine 2,3-dioxygenase inhibitors
10.2147/OTT.S119362 ↗17. Dhiman, V., Giri, K.K., Zainuddin, M., Rajagopal, S., and Mullangi, R. (2017). Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. Biomed. Chromatogr., 31.
10.1002/bmc.3794 ↗18. Quantification of Linrodostat and its metabolites: Overcoming bioanalytical challenges in support of a discovery Indoleamine 2,3 dioxygenase program
10.1016/j.jchromb.2022.123305 ↗21. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
10.1093/neuonc/noad174 ↗22. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression
10.1016/j.intimp.2024.112437 ↗23. Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo-Immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment
10.1002/adma.202307263 ↗24. Hypoxia-Specific Metal-Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound
10.1021/acsnano.4c02921 ↗25. Dual-Responsive Supramolecular Polymeric Nanomedicine for Self-Cascade Amplified Cancer Immunotherapy
10.1002/advs.202305382 ↗27. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors
10.1016/j.ejmech.2020.112059 ↗28. Peyraud, F., Guegan, J.P., Bodet, D., Cousin, S., Bessede, A., and Italiano, A. (2022). Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives. Front. Immunol., 13.
10.3389/fimmu.2022.807271 ↗29. Yang, C., Ng, C.T., Li, D., and Zhang, L. (2021). Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation. Front. Immunol., 12.
10.3389/fimmu.2021.725204 ↗30. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy
10.1016/j.bioorg.2018.02.010 ↗31. Wen, H., Liu, Y., Wang, S., Wang, T., Zhang, G., Chen, X., Li, Y., Cui, H., Lai, F., and Sheng, L. (2019). Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents. Molecules, 24.
10.3390/molecules24112124 ↗33. Liu, X., Wang, H., Li, Z., Li, J., He, S., Hu, C., Song, Y., Gao, H., and Qin, Y. (2024). Transformable self-delivered supramolecular nanomaterials combined with anti-PD-1 antibodies alleviate tumor immunosuppression to treat breast cancer with bone metastasis. J. Nanobiotechnol., 22.
10.1186/s12951-024-02839-0 ↗34. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway
10.1002/adma.202102188 ↗35. Overcoming Chemoimmunotherapy-Induced Immunosuppression by Assemblable and Depot Forming Immune Modulating Nanosuspension
10.1002/advs.202102043 ↗36. Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer
10.1002/advs.201903332 ↗37. An Activatable Dual Polymer Nanosystem for Photoimmunotherapy and Metabolic Modulation of Deep-Seated Tumors
10.1002/adhm.202303305 ↗39. Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid
10.2147/IJN.S240436 ↗40. Meng, X.B., Chen, Y., Li, Z.J., and Zhang, M.Q. (2017). Nitrogen Heterocyclic Tryptamine Ketone Derivative and Application as IDO1 and TDO Inhibitor. (CN107260743A).
41. Self-Splittable Transcytosis Nanoraspberry for NIR-II Photo-Immunometabolic Cancer Therapy in Deep Tumor Tissue
10.1002/advs.202204067 ↗42. Tumor Microenvironment Activated Photoacoustic-Fluorescence Bimodal Nanoprobe for Precise Chemo-immunotherapy and Immune Response Tracing of Glioblastoma
10.1021/acsnano.3c03378 ↗44. Dai, L.L., Li, X., Yao, M.J., Niu, P.Y., Yuan, X.C., Li, K., Chen, M.W., Fu, Z.X., Duan, X.L., and Liu, H.B. (2020). Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy. Biomaterials, 241.
10.1016/j.biomaterials.2020.119901 ↗45. Paraptosis Inducer to Effectively Trigger Immunogenic Cell Death for Metastatic Tumor Immunotherapy with IDO Inhibition
10.1021/acsnano.2c11964 ↗46. Li, Z., Wang, J., Liu, J., Yu, J., Wang, J., Wang, H., Wei, Q., Liu, M., Xu, M., and Feng, Z. (2024). Multifunctional ZnO@DOX/ICG-LMHP Nanoparticles for Synergistic Multimodal Antitumor Activity. J. Funct. Biomater., 15.
10.3390/jfb15020035 ↗47. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy
10.1016/j.actbio.2022.07.022 ↗49. Meireson, A., Devos, M., and Brochez, L. (2020). IDO Expression in Cancer: Different Compartment, Different Functionality?. Front. Immunol., 11.
10.3389/fimmu.2020.531491 ↗51. Amino acid metabolism in immune cells: Essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy
10.1186/s13045-023-01453-1 ↗52. Hornyák, L., Dobos, N., Koncz, G., Karányi, Z., Páll, D., Szabó, Z., Halmos, G., and Székvölgyi, L. (2018). The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy. Front. Immunol., 9.
10.3389/fimmu.2018.00151 ↗53. Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth
10.1136/jitc-2021-003623 ↗54. Guo, Y.X., Liu, Y., Wu, W., Ling, D.S., Zhang, Q., Zhao, P., and Hu, X. (2021). Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials, 276.
10.1016/j.biomaterials.2021.121018 ↗56. Low-Field NMR to Characterize the Crystalline State of Ibuprofen Confined in Ordered or Nonordered Mesoporous Silica
10.1248/cpb.c22-00180 ↗58. Ultrasmall Cu(I) Nanoparticles Stabilized on Surface of HPMC: An Efficient Catalyst for Fast and Organic Solvent-Free Tandem Click Chemistry in Water
10.1002/cssc.202201826 ↗59. Touqeer, S.I., Jahan, N., Abbas, N., and Ali, A. (2022). Formulation and Process Optimization of Rauvolfia serpentina Nanosuspension by HPMC and In Vitro Evaluation of ACE Inhibitory Potential. J. Funct. Biomater., 13.
10.3390/jfb13040268 ↗60. Jahan, N., Kousar, F., Rahman, K.U., Touqeer, S.I., and Abbas, N. (2023). Development of Nanosuspension of Artemisia absinthium Extract as Novel Drug Delivery System to Enhance Its Bioavailability and Hepatoprotective Potential. J. Funct. Biomater., 14.
10.3390/jfb14080433 ↗62. Paclitaxel-loaded magnetic nanocrystals for tumor neovascular-targeted theranostics: An amplifying synergistic therapy combining magnetic hyperthermia with chemotherapy
10.1039/D0NR08197C ↗63. Nguyen, T.T., Duong, V.A., and Maeng, H.J. (2021). Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics, 13.
10.3390/pharmaceutics13071103 ↗64. Vrettos, N.N., Roberts, C.J., and Zhu, Z. (2021). Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications. Pharmaceutics, 13.
10.3390/pharmaceutics13101591 ↗65. Non-invasive optical imaging of retinal Aβ plaques using curcumin loaded polymeric micelles in APP(swe)/PS1(ΔE9) transgenic mice for the diagnosis of Alzheimer’s disease
10.1039/D0TB01101K ↗66. Mixed polyethylene glycol-modified breviscapine-loaded solid lipid nanoparticles for improved brain bioavailability: Preparation, characterization, and in vivo cerebral microdialysis evaluation in adult Sprague Dawley rats
10.1208/s12249-014-0080-4 ↗67. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
10.2147/DDDT.S373780 ↗68. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
10.1158/1078-0432.CCR-23-0535 ↗70. A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
10.1007/s10637-020-00950-1 ↗71. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
10.1158/1078-0432.CCR-16-2272 ↗72. Oral administration of nanoformulated indoximod ameliorates ulcerative colitis by promoting mitochondrial function and mucosal healing
10.1016/j.ijpharm.2023.122813 ↗73. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles
10.1016/j.phrs.2017.09.004 ↗74. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy
10.1021/acsami.4c02740 ↗77. Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase
10.1177/11786469221138456 ↗78. Chen, X., Xu, D., Yu, J., Song, X.J., Li, X., and Cui, Y.L. (2024). Tryptophan Metabolism Disorder-Triggered Diseases, Mechanisms, and Therapeutic Strategies: A Scientometric Review. Nutrients, 16.
10.3390/nu16193380 ↗80. Kim, M., and Tomek, P. (2021). Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO. Front. Immunol., 12.
10.3389/fimmu.2021.636081 ↗